News

Deal Announcements

MabVax Adds Venture Capital Funding

Monday, November 26, 2012 5:32:00 AM PDT | VentureDeal
   San Diego, California  --  Biotechnology company MabVax Therapeutics has garnered $5.25 million in follow-on venture capital funding.

MabVax is developing novel vaccines and human antibodies for the treatment of cancer.

Numoda Capital Innovations led the round, which also included previous investors Burrill & Co. and RTP Ventures.

MabVax said it would use the financing to continue development of its most promising treatment candidates.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1